Simulations Plus (SLP) – Research Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Simulations Plus (NASDAQ: SLP):

• 10/8/2025 – Simulations Plus had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/30/2025 – Simulations Plus is now covered by analysts at Cowen Inc. They set a “hold” rating on the stock.
• 9/30/2025 – Simulations Plus is now covered by analysts at TD Cowen. They set a “hold” rating and a $16.00 price target on the stock.
• 9/27/2025 – Simulations Plus had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.